SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

2
Policy
Jazz and Redx Tout IND Acceptance while Omega Seeks First
Jazz Pharmaceuticals, Redx Pharma and Omega Therapeutics are pushing forward with their cancer treatments with Investigational New Drug approval and IND application submission.
June 15, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
COVID-19 Research: Paxlovid Disappoints in Standard-Risk Setting, Nasal Spray Offers New Hope
Biopharma has been stepping up research and drug development against COVID-19 -though results haven’t always been encouraging. Here are the latest stories from this space:
June 15, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Soleno Soars on Positive Prader-Willi Syndrome Data
Soleno announced promising results of its diazoxide choline extended-release tablets in patients with Prader-Willi syndrome at ENDO 2022.
June 14, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Versanis Hopes to Compete with Lilly, Novo in Weight Loss Space
Versanis Bio’s data reveals the results of a pooled analysis, showing that its lead asset, bimagrumab, improves body composition in both diabetic and non-diabetic patients.
June 13, 2022
 · 
3 min read
 · 
Tristan Manalac
Tahi Ahmadi/both courtesy of Genmab
Drug Development
AbbVie & Genmab EHA Data Indicate LBCL Drug Could Fill Unmet Need
Genmab’s Phase II expansion cohort of the EPCORE NHL-1 clinical trial revealed that its investigational bispecific antibody epcoritamab induced a durable response in patients with LBCL.
June 13, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Abbvie Inc.
Business
AbbVie Touts New Data for Rare Blood Cancer & Leukemia Treatments
AbbVie announced Friday that its investigational drug navitoclax, when used together with ruxolitinib, eases symptoms in myelofibrosis patients who had not yet been treated with a JAK inhibitor.
June 10, 2022
 · 
2 min read
 · 
Tristan Manalac
Blood Test, Blood, Medical Sample, Test Tube
Drug Development
Roche, ADC and Caribou Get the Blood Pumping at EHA
The European Hematology Association’s 2022 Hybrid Congress is in full swing in Vienna, Austria and will feature the newest and most promising developments in blood cancer research.
June 10, 2022
 · 
5 min read
 · 
Tristan Manalac
Degron Co-founder and CEO Lily Zou, Ph.D/courtesy
Business
Degron Therapeutics Launches into Sizzling Hot Protein Degradation Space
Degron Therapeutics, based in Shanghai, announced Thursday that it has secured $22 million in Series A financing for its unique molecular glue-based targeted protein degradation platform GlueXplorer.
June 9, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Annexon Engages the Target, Sees Stabilization in Phase II Huntington’s Trial
Annexon released final data from an open-label phase II clinical trial, showing that its drug candidate ANX005 safely stabilized disease progression in patients with Huntington’s disease.
June 8, 2022
 · 
3 min read
 · 
Tristan Manalac
Courtesy of Getty Images
Drug Development
Lilly’s Mounjaro Bests Novo’s Diabetes Drugs in Comparison Study
The Phase I mechanism of action study, showing that Lilly’s injectable Mounjaro (tirzepatide) induces greater weight loss than placebo and Novo Nordisk’s semaglutide in adults with type 2 diabetes.
June 7, 2022
 · 
2 min read
 · 
Tristan Manalac
A Novartis building under a blue sky/courtesy of C
Drug Development
Novartis Combo could be New Standard of Care for Pediatric Glioma Patients
Results of a Phase II/III study showed that patients who were given Tafinlar plus Mekinist saw an overall response rate of 47% vs. 11% for those who received standard chemotherapy only.
June 7, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Real World Study Demonstrates Consistent Survival for Gilead’s Yescarta Across Race/Ethnicity
The study revealed that Yescarta was both safe and effective in adult patients regardless of race and ethnicity.
June 6, 2022
 · 
2 min read
 · 
Tristan Manalac
Load More